Applicant, as named in the Orange Book
Viiv Hlthcare
Next listed expiry: Rukobia on 13 Jul 2029. 10 products with live protection, 8 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Rukobia fostemsavir tromethamine | 13 Jul 2029 |
| Tivicay dolutegravir sodium | 8 Jun 2030 |
| Tivicay Pd dolutegravir sodium | 8 Jun 2030 |
| Triumeq abacavir sulfate; dolutegravir sodium; lamivudine | 8 Jun 2030 |
| Triumeq Pd abacavir sulfate; dolutegravir sodium; lamivudine | 8 Jun 2030 |
| Dovato dolutegravir sodium; lamivudine | 24 Jan 2031 |
| Vocabria cabotegravir sodium | 4 Feb 2031 |
| Apretude cabotegravir | 15 Sep 2031 |
| Juluca dolutegravir sodium; rilpivirine hydrochloride | 5 Sep 2038 |
| Cabenuva Kit · 2 strengths cabotegravir; rilpivirine | 1 Oct 2040 |
Recent events
- 25 Oct 2026Selzentry · Generic approved 4 Nov 2025
- 24 Oct 2026Triumeq · Exclusivity expires within 90 days PED15 Dec 2026
- 24 Oct 2026Triumeq Pd · Exclusivity expires within 90 days PED15 Dec 2026
Products without listed protection (8)
| Drug | Earliest generic entry |
|---|---|
| Epivir lamivudine | open now |
| Epivir · 2 strengths lamivudine | open now |
| Retrovir zidovudine | open now |
| Retrovir zidovudine | open now |
| Retrovir zidovudine | open now |
| Selzentry maraviroc | open now |
| Selzentry · 2 strengths maraviroc | open now |
| Ziagen abacavir sulfate | open now |